Today it was reported that the CEO of VistaGen Therapeutics (VTGN), Shawn Singh, exercised options to buy 25,375 VTGN shares at $1.50 a share, for a total transaction value of $38.06K.
This recent transaction increases Shawn Singh’s holding in the company by 114.77% to a total of $87.74K.
See today’s analyst top recommended stocks >>
Currently, VistaGen Therapeutics has an average volume of 88.32K. The Company has a Price to Book ratio of 12.2329.
Starting in February 2018, VTGN received 18 Buy ratings in a row.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines for depression and other diseases and disorders of the central nervous system. It focuses on AV-101 product, an oral, non-opioid and non-sedating therapy that offers the potential to be a new at-home treatment for multiple central nervous system indications with high-unmet medical need. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
